港股異動 | 中煙香港(6055.HK)高開3.35% 預期中期淨利潤增幅不低於115%
格隆匯6月10日丨中煙香港(6055.HK)高開3.35%,報18.5港元,最新市值127.96億港元。中煙香港昨日晚間發公吿稱,截至2021年6月30日止6個月與2020年同期相比,預期公司將錄得收入增幅不低於85%,淨利潤增幅不低於115%。預期收入及淨利潤增加乃主要歸因於(i)公司與產業鏈上下游密切溝通,盡最大努力減輕新冠肺炎疫情對供應鏈物流的影響,使2020年度延遲裝運的煙葉類進口產品於期間陸續到港,令2021年上半年煙葉類產品進口業務的收入大幅上升;及(ii)公司大力推行"降增效",控制費用開支,使行政及其他經營開支與2020年同期基持平。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.